BiotechTube
Biomosaics

Biomosaics

Boston, United States· Est.
biomosaics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.8M

Overview

BioMosaics is a private, revenue-generating diagnostics company focused on the Glypican-3 (GPC3) biomarker for liver cancer. The company commercializes a suite of validated antibodies and immunoassays, including its CanAg® EIA, primarily for research and clinical diagnostic use. With a leadership team experienced in biotechnology and academic research, and key scientific partnerships, BioMosaics positions itself as a quality provider in the niche GPC3 diagnostics space. The company's products support the broader therapeutic development landscape targeting GPC3 in oncology.

Oncology

Technology Platform

Development and validation of monoclonal antibodies and immunoassays (IHC, ELISA) for the detection of the Glypican-3 (GPC3) biomarker.

Funding History

1
Total raised:$2.8M
Seed$2.8M

Opportunities

The surge in development of GPC3-targeting cell and gene therapies (e.g., CAR-T, mRNA CAR) creates a growing, parallel demand for high-quality detection tools for patient stratification and biomarker analysis.
BioMosaics can leverage its first-mover expertise to establish formal companion diagnostic partnerships with therapeutic companies, transitioning from a research supplier to a critical clinical trial and commercial partner.

Risk Factors

The company faces extreme concentration risk, as its entire business is tied to the scientific and clinical utility of a single biomarker, GPC3.
It also competes indirectly with large, well-capitalized life science tools companies that could rapidly enter the space with competing assays, threatening its market position.

Competitive Landscape

BioMosaics competes in the niche segment of GPC3-specific reagents. While large, broad-based reagent vendors (e.g., Abcam, Cell Signaling Technology, R&D Systems) offer GPC3 antibodies, BioMosaics differentiates through deep specialization, validation specifically for HCC, and a focused product suite. Its main competition likely comes from in-house assay development by large pharmaceutical companies and academic labs, though its commercial, off-the-shelf validated products offer consistency and time savings.

More companies in Diagnostics & Precision Medicine →More companies in United States →